Study on Clinical Features, Treatment Mode and Survival of Sarcoma
A Single-center Retrospective Study of Clinical Features, Treatment Patterns, and Survival of Sarcomas
1 other identifier
observational
6,000
1 country
1
Brief Summary
The clinical data of all eligible patients who received chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy and surgery in Henan Tumor Hospital from June 1, 2012 to May 30, 2022 were retrospectively collected.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2022
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 7, 2022
CompletedFirst Submitted
Initial submission to the registry
July 6, 2022
CompletedFirst Posted
Study publicly available on registry
July 12, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2024
CompletedFebruary 7, 2024
December 1, 2023
2.6 years
July 6, 2022
February 5, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
Progression-free survival
Progression-free survival is defined as time from enrollment to the first occurrence of progression of disease or death from any cause within 63 days of last response assessment.
Up to approximately 24months
Overall survival
Time from pathological diagnosis to death
Up to approximately 120months
Interventions
No intervention
Eligibility Criteria
Sarcoma patients receiving inpatient treatment in Henan Tumor Hospital.
You may qualify if:
- No age limit, male or female. A certain subtype of sarcoma was diagnosed by pathology in our hospital. Has received at least one hospitalization in this hospital. Target lesions can be evaluated according to solid tumor efficacy evaluation criteria (RECIST; Version 1.1) Measure diameter changes.
- Complete follow-up data.
You may not qualify if:
- No clear pathology. Incomplete follow-up data.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Bone and Soft Tissue ,Henan Cancer Hospital
Zhengzhou, Henan, 450008, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate chief physician
Study Record Dates
First Submitted
July 6, 2022
First Posted
July 12, 2022
Study Start
June 7, 2022
Primary Completion
December 31, 2024
Study Completion
December 31, 2024
Last Updated
February 7, 2024
Record last verified: 2023-12